Results from laboratory experiments and mouse studies suggest that small doses of drugs from a specific class of approved cancer medications called topoisomerase 1 (top1) inhibitors may protect against the overwhelming immune response to infection that sometimes leads to sepsis, a bacterial condition that kills as many as 500,000 people in the United States each year. The research, supported in part by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), appears in the April 28, 2016 issue of Science.
Viral and bacterial infections can cause the human body to produce a massive inflammatory response leading to sepsis, which often results in tissue damage, organ failure and in some cases, death. Anyone with an infection can develop sepsis; however, people with weakened immune systems; babies and young children; the elderly; individuals with chronic illnesses, such as diabetes; and people with severe burns and wounds are at greatest risk. Viruses such as Ebola and novel influenza strains also can trigger similar and sometimes deadly immune responses. Treatments to dampen this over-exuberant inflammatory response without weakening the body's ability to fight infection are urgently needed, according to the authors.
Led by scientists from the Icahn School of Medicine at Mount Sinai in New York, the research team conducted laboratory experiments that revealed that during infection the enzyme topoisomerase 1 activates genes that produce a strong inflammatory response. This suggested that impeding the enzyme could be an effective way to suppress an overwhelming inflammatory response while still allowing the normal immune response to work.
The scientists found that 70 to 90 percent of mice treated with one to three doses of the top1 inhibitor cancer drug camptothecin were rescued from a lethal inflammatory response caused by infection with the bacteria Staphylococcus aureus (S. aureus), co-infection with influenza and S. aureus, or liver failure. A laboratory experiment also found that inhibiting topoisomerase 1 in human cells suppressed inflammatory genes induced by Ebola virus. Together, the data suggest that anti-top1 cancer drugs potentially could help control acute infections that induce an exacerbated inflammatory response and deserve further exploration, according to the researchers.
A Rialdi et al. Topoisomerase 1 inhibition suppresses the transcriptional activation of innate immune responses and protects against inflammation-induced death. Science DOI: 10.1126/science.aad7993 (2016).
NIAID Director Anthony S. Fauci, M.D., and Vivien G. Dugan, Ph.D., Systems Biology program officer in in NIAID's Division of Microbiology and Infectious Diseases, are available for comment.
To schedule interviews, please contact Jennifer Routh, 301-402-1663, firstname.lastname@example.org.
NIAID conducts and supports research -- at NIH, throughout the United States, and worldwide -- to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.